1 474

Cited 200 times in

Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy.

Authors
 PH Lee  ;  JW Kim  ;  OY Bang  ;  YH Ahn  ;  IS Joo  ;  K Huh 
Citation
 CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.83(5) : 723-730, 2008 
Journal Title
CLINICAL PHARMACOLOGY & THERAPEUTICS
ISSN
 0009-9236 
Issue Date
2008
MeSH
Brain/diagnostic imaging ; Brain/pathology ; Disease Progression ; Feasibility Studies ; Female ; Fluorodeoxyglucose F18 ; Humans ; Male ; Mesenchymal Stem Cell Transplantation*/adverse effects ; Middle Aged ; Multiple System Atrophy/diagnostic imaging ; Multiple System Atrophy/pathology ; Multiple System Atrophy/surgery* ; Positron-Emission Tomography ; Prospective Studies
Keywords
Brain/diagnostic imaging ; Brain/pathology ; Disease Progression ; Feasibility Studies ; Female ; Fluorodeoxyglucose F18 ; Humans ; Male ; Mesenchymal Stem Cell Transplantation*/adverse effects ; Middle Aged ; Multiple System Atrophy/diagnostic imaging ; Multiple System Atrophy/pathology ; Multiple System Atrophy/surgery* ; Positron-Emission Tomography ; Prospective Studies
Abstract
We evaluated the feasibility and safety of therapy with mesenchymal stem cells (MSCs) through consecutively intra-arterial and three repeated intravenous injections and compared the long-term prognosis between MSC-treated (n=11) and control multiple system atrophy (MSA) patients (n=18). The MSC-treated patients showed significantly greater improvement on the unified MSA rating scale (UMSARS) than the control patients at all visits throughout the 12-month study period. Orthostasis in UMSARS I items and cerebellar dysfunction-related items of UMSARS II items were significantly different in favor of MSC treatment compared to controls. Serial positron emission tomography scan in the MSC-treated group showed that increased fluorodeoxyglucose uptake from baseline was noted in cerebellum and frontal white matters. No serious adverse effects related to MSC therapy occurred. This study demonstrated that MSC therapy in patients with MSA was safe and delayed the progression of neurological deficits with achievement of functional improvement in the follow-up period.
Full Text
http://www.nature.com/clpt/journal/v83/n5/full/6100386a.html
DOI
10.1038/sj.clpt.6100386
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Neurology (신경과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Phil Hyu(이필휴) ORCID logo https://orcid.org/0000-0001-9931-8462
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/108078
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links